Introduction
Bipolar I and II disorder, which is a mental health condition characterized by frequent mood shifts from the highest to the lowest, creates a catastrophic effect on one’s well-being. This disorder is characterized by changes in extreme feelings: highs (mania or hypomania) and lows (depression) that interfere with normal living and affect relationships. It is not just the individuals who are stricken; this pestilence also affects families, communities, and society in great measure.
The World Health Organization (2020) estimated that bipolar I and II disorders affect 40 million globally. The economic toll of the illness is significant; it causes low productivity, high healthcare costs, and a higher incidence of disability. The insight into the intricacies of bipolar disorder is a prerequisite for taking measures for better treatment and assistance.
Pathophysiology
Bipolar I and Bipolar Disorder II are mental disorders of particular difficulty and are classified by several patterns of mood disturbances. The complex physiological, psychological, and environmental influences determine the pathogenesis of both diseases. The biological foundations of Bipolar I disorder refer to the impairment of neurotransmitter systems, more specifically, the imbalances in dopamine and serotonin (Young & Juruena, 2021).
Disturbances in the levels of these neurotransmitters, along with other altered neurochemical elevations, are involved in the manifestation and maintenance of manic episodes. Among individuals with Bipolar I Disorder, anatomic and functional brain alterations can be noted (Young & Juruena, 2021). The changes can be observed in the prefrontal cortex, amygdala, and hippocampus, which are crucial brain areas involved in mood regulation and emotional processing.
Conversely, Bipolar II Disorder consists of hypomanic phases and major depression that have recurring cycles. The hypomanic disorder is like mania but with less serious symptoms and without lasting for a long period (Magioncalda& Martino, 2022). Although the symptoms of hypomania still affect everyday functioning, they may, in extreme cases, lead to complete manic episodes. Like Bipolar I Disorder, Bipolar II Disorder pathogenesis involves dysfunction in neurotransmitter systems along with brain-structural abnormalities.
Nevertheless, the aspect that differentiates these abnormalities is that hypomania is characterized by less severe and shorter mood disturbances in comparison to mania (Young & Juruena, 2021). The art of neuroimaging has shown changes in the same brain areas in Bipolar Disorder I (Magioncalda & Martino, 2022). This facet could be evidence of a common neurobiological background for both kinds.
Just like it happens in the case of Bipolar I and Bipolar II Disorder, genetic factors equally play a role in pathophysiological features. Family and twin studies repeatedly suggest that the first-degree relatives of those diagnosed with bipolar disorder have higher identical zygosity than the general population (Huang et al., 2021). Some sensitive genes have been linked to this predisposition, including those involved in neurotransmitter signaling, circadian rhythm regulation, and neuronal development.
Not only environmental factors, such as exposure to stress, trauma, and substance abuse, but also intrinsic factors, such as frequently occurring mood episodes, are involved in the pathophysiology of bipolar disorder. Prolonged stress causes an imbalance in the hypothalamic-pituitary-adrenal (HPA) axis, leading to disturbances in cortisol levels and an increased risk of depression (Magioncalda & Martino, 2022). In addition, people with bipolar disorder have a history of adversity during childhood and interpersonal conflicts that could contribute to the onset and severity of this condition.
Diagnostic Criteria
Differences in the type and intensity of mood impairments play a central role in the contrast between Bipolar I and II disorders. Based on the DSM-5 classification, Bipolar I Disorder is diagnosed when a person has experienced at least one full-blown manic episode that is often preceded by either a hypomanic or major depressive episode (Erten, 2021). A manic episode is defined as an individual’s distinct period of an abnormally persistent and elevated, expansive, or irritable mood for at least 7 days, or any duration if the person requires hospitalization (Erten, 2021).
During a manic episode, individuals may also feel hyperactivity, that is, increased energy, a tendency to be restless, and trouble sleeping, as well as grandiosity, racing thoughts, and impulsivity. Furthermore, maniac interludes may be accompanied by significant impairment in social and occupational life or may necessitate urgent admissions to prevent self-harm or harming other people.
On the contrary, Bipolar II Disorder diagnosis entails experiencing at least one hypomanic episode and a major depressive episode. A hypomanic state resembles a manic episode but is not as intense, and it does not cause severe functional impairment, or hospitalization is usually required (Makowski et al., 2023). It could be distinguished by the experience of manic episodes, which are symptoms of mood swings lasting four days or more (Erten, 2021).
Furthermore, a significant event of at least one major depressive episode that goes on for not less than two weeks is what is needed to diagnose Bipolar II Disorder. Rolin et al. (2020) note that major depressive episodes consist of symptoms including depressed mood, loss of interest or pleasure in activities, significant change in weight, insomnia or hypersomnia, psychomotor agitation or retardation, tiredness all the time, low self-worth, and feeling guilty. Episodes of mood in Bipolar II Disorder go beyond the clinically significant disturbance or impairment in the social, occupational, or any other important areas of functioning.
Treatment
Pharmacological Interventions
The treatment methods for bipolar disorder are complex and involve the use of not only drug use but also non-drug use interventions, as they have various roles in addressing different aspects of the condition. Pharmacological interventions play a central part in dealing with bipolar disorder. Drugs aim to balance both mood stabilization and somatic symptoms. Mood stabilizers have an important role in bipolar treatment, which is to calm down and prevent the mood from becoming too high or too low.
Lithium, widely used for the treatment of mood disorders, has won a reputation as effective in diminishing the strength and frequency of mood episodes, especially manic ones (Yalin & Young, 2020). It does this by interfacing several neurotransmitter systems, such as serotonin and norepinephrine, which stabilize mood. Valproate, another frequently used mood stabilizer, is a secretin that boosts gamma-aminobutyric acid (GABA), which causes anti-convulsive and mood-stabilizing effects (Yalin & Young, 2020). Lamotrigine was initially discovered to be an anti-epileptic agent, but it has proved to be useful in managing depressive episodes of bipolar disorder by regulating the release of glutamate.
Moreover, second-generation antipsychotics (SGAs) are often utilized in the treatment of bipolar disorder, particularly in mania and mixed episodes. Antipsychotics of the SGA group (quetiapine, olanzapine, and risperidone) are widely used for their stabilizing effect on dopamine receptors (Yalin& Young, 2020). As a result, agitation, psychosis, and impulsivity related to manic symptoms are diminished. Additionally, they can be used to continue treatment and reduce the risk of depressive episodes and to maintain mood in the long run (Yalin & Young, 2020). These agents, therefore, become front-line drugs of choice owing to the negligible extrapyramidal side effects when compared with first-generation antipsychotics.
Furthermore, antidepressants in bipolar disorder care are commonly but cautiously prescribed to tackle the depressive symptoms of the disease. Nevertheless, these treatments are frequently linked to the risk of inducing manic or hypomanic episodes. Thus, Yalin and Young (2020) suggest that antidepressants are usually given together with mood stabilizers or antipsychotics to diminish this risk and get the best mood stability. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are typically the first choice of antidepressants in bipolar depression (Edinoff et al., 2021). However, tricyclic Antidepressants and Monoamine Oxidase Inhibitors are also considered in some cases, often under close monitoring and sometimes with a mood stabilizer co-medication.
Non-Pharmacological Interventions
Besides drug therapy, non-pharmacological treatments are important parts of the treatment of bipolar I and II disorders. Treatment of bipolar disorder essentially stems from psychotherapies, which come in different forms that are suitable for the individual depending on their unique situation. Cognitive-behavioral therapy (CBT) involves focused work on how one thinks and behaves, with a focus on negative cognitive patterns, maladaptive behaviors, and distressing mood swings (Miklowitz et al., 2021).
By providing practical techniques to counter-identify and regulate emotions, CBT empowers participants to control their symptoms. CBT empowers individuals by helping them manage their conditions and prevent relapses. Moreover, the therapy aims to improve one’s self-awareness and encourage permanent behavior changes (Miklowitz et al., 2021). This aspect is useful in the long-term treatment of bipolar disorders.
Interpersonal and social rhythm therapy (IPSRT) appreciates the role of predictable daily rituals and healthy relationships against bipolar disorder. Rhythm stabilization, in which the sleep schedule is regulated, and social interactions and daily activities are focused, is the major task of IPSRT, through which regularity and stable mood emerge (Alam et al., 2022). Moreover, family-focused therapy (FFT) is based on the realization that one of the effects that bipolar disorder has is on family relationships, which is factored into the treatment process by involving friends and kin. By fostering open communication, problem-solving, and mutual support, FFT helps the family become cohesive and functionally sound.
At the same time, the individual with bipolar disorder may find the supportive environment of such an aftercare program helpful. Such psychotherapeutic interventions not only address the acute symptoms of this illness but also equip individuals with work-life skills that are instrumental in combating this chronic disorder (El-Bilsha et al., 2021). Psychotherapy performs a major treatment role in bipolar disorder treatment plans, where it acts to ensure stability, improve social support, facilitate coping skills, and consequently improve life quality and long-term outcomes for the people living with this condition.
On the other hand, it is the lifestyle interventions that prove their effectiveness in stabilizing the condition and lessening the symptoms of bipolar disorder. Research shows that incorporating exercise into daily life can lead to significant improvements in mood. As a result, it promotes general well-being and reduces the prevalence of depressive symptoms (Moussa et al., 2023).
In addition, maintaining a regular sleep schedule can promote mood stability and evenness by regulating circadian rhythms. It is highly recommended not to abuse substances, for instance, alcohol and drugs, that have side effects of mood disorders and could, at the same time, disrupt the treatment of the illness (Moussa et al., 2023). Moreover, providing a planned daily model that reflects physical and mental health, good dietary intake, and anxiety management skills can help maintain good mental health and ensure better outcomes during treatment.
Along with conventional therapeutic methods, these lifestyle implications operate as backup and prompt individuals to be more active in caring for their conditions. Integrating these actions into a person’s daily routine has a positive effect on the surrounding environment, which plays a vital role in an individual’s mental health (Moussa et al., 2023). Apart from involving lifestyle interventions along with pharmacotherapy and psychotherapy, the management of bipolar disorders becomes more holistic, where they address the multi-faceted nature of the disease and promote comprehensive well-being. Thus, both cognitive-behavioral therapy and lifestyle interventions are essential in a comprehensive treatment plan for bipolar disorder.
Conclusion
Bipolar I and II disorder, a complex illness, affects people in different ways across their families and societies. Awareness of the pathophysiology, diagnostic criteria, and available treatment options is integral to effective management. The intricate interplay among genetic, neurobiological, and environmental pathways underscores the complexity of this condition. Genetic predisposition, neurotransmitter dysfunction, and structural brain changes constitute the core of mood disturbances of Depressive and Manic Bipolar Disorders. Continuous environmental stressors make symptoms more severe and reaffirm the requirement for holistic treatment plans.
Management of bipolar disorder takes varying approaches, which include medication and non-pharmacological therapies. Pharmacological interventions include mood stabilizers, antipsychotics, and antidepressants, which are used to control moodiness through which psychotherapy, lifestyle changes, and adjustments are made to promote stability and wellness. Cognitive-behavioral therapy is driven by eradicating negative cognitive patterns, enabling patients to control their symptoms. Lifestyle interventions, including regular exercise, sleep regulation, and stress management, provide additional support for traditional treatment, thereby increasing resilience and treatment effectiveness. Early diagnosis allows an individual to benefit from exploring options, receive relevant assistance, and plan well.
References
Alam, F. H., El Fiky, E. R., & El-Amrosy, S. H. (2022). Efficacy of interpersonal and social rhythm therapy on sleep disorders and psychological adjustment among patients with bipolar disorder. Tanta Scientific Nursing Journal, 27(4), 159-173.
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. A., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., Cornett, E. M., & Kaye, A. M. (2021). Selective Serotonin Reuptake inhibitors and adverse effects: A narrative review. Neurology International, 13(3), 387–401.
El-Bilsha, M., El-hadidy, M., & Aid, A. (2021). Social support and its relevance to relapse among patients with bipolar disorder. Mansoura Nursing Journal, 8(1), 103-113.
Erten, E. (2021). Acute and maintenance treatment of bipolar depression. Archives of Neuropsychiatry, 58(Suppl 1), S31.
Huang, M.-H., Cheng, C.-M., Tsai, S.-J., Bai, Y.-M., Li, C.-T., Lin, W.-C., Su, T.-P., Chen, T.-J., & Chen, M.-H. (2020). Familial coaggregation of major psychiatric disorders among first-degree relatives of patients with obsessive-compulsive disorder: A nationwide study. Psychological Medicine, 1–8.
Magioncalda, P., & Martino, M. (2022). A unified model of the pathophysiology of bipolar disorder. Molecular Psychiatry, 27(1), 202-211.
Makowski, A., Gray, H., & Perry, J. (2023). Depressive episodes in a patient with bipolar disorder. The Journal for Nurse Practitioners, 19(8).
Miklowitz, D. J., Efthimiou, O., Furukawa, T. A., Scott, J., McLaren, R., Geddes, J. R., & Cipriani, A. (2021). Adjunctive psychotherapy for bipolar disorder: A systematic review and component network meta-analysis. JAMA Psychiatry, 78(2), 141-150.
Moussa, A. E. N., Awad, A., Harfush, A. E. G., Abd El-Menem, S., & Tawfik, A. E. (2023). Effectiveness of lifestyle intervention on recovery of patients with bipolar disorders. Tanta Scientific Nursing Journal, 30(3), 26-47.
Rolin, D., Whelan, J., & Montano, C. B. (2020). Is it depression or is it bipolar depression? Journal of the American Association of Nurse Practitioners, 32(10), 703-713.
World Health Organization. (2022). Mental disorders. World Health Organization; World Health Organization.
Yalin, N., & Young, A. H. (2020). Pharmacological treatment of bipolar depression: What are the current and emerging options? Neuropsychiatric Disease and Treatment, 1459-1472.
Young, A. H., & Juruena, M. F. (2021). The neurobiology of bipolar disorder. Bipolar Disorder: From Neuroscience to Treatment, 1-20.